Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial

2016422 citationsJournal Article

Authors

Good health and well-being

Published in: The Lancet Oncology

Volume 17, Issue 3, pp. 378-388

Field-Weighted Citation Impact: 40.23